Eiger Biopharmaceuticals Garners $7,100,000 Series A Round

  • Feed Type
  • Date
    2/24/2009
  • Company Name
    Eiger Biopharmaceuticals
  • Mailing Address
    3350 West Bayshore Road Palo Alto, CA 94303
  • Company Description
    Eiger BioPharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. Eiger’s pipeline includes repurposed clinical agents as well as preclinical new chemical entities (NCEs) from its discovery research shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses.
  • Website
    http://www.eigerbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $7,100,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funding will advance the company’s lead program targeted against NS4B, a specific region in the hepatitis C virus (HCV) protein, as well as progress lead identification for other proprietary targets.
  • M&A Terms
  • Venture Investor
    InterWest Partners
  • Venture Investor
    Vivo Ventures

By posting a comment, you agree to our terms and conditions.